НовостиBenzingaMorgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53 Morgan Stanley Maintains Overweight on Avalyn Pharma, Lowers Price Target to $53 Benzinga 2026.11.16 15:00 (GMT+0) Открыть на Benzinga Другие новости